4.5 Article

Tumor-suppression functions of merlin are independent of its role as an organizer of the actin cytoskeleton in Schwann cells

期刊

JOURNAL OF CELL SCIENCE
卷 122, 期 22, 页码 4141-4149

出版社

COMPANY BIOLOGISTS LTD
DOI: 10.1242/jcs.045914

关键词

Neurofibromatosis type 2; Merlin; Ezrin; Schwann cells; FERM domain; Proliferation; Cytoskeleton; Protein domains

资金

  1. US Department of Defense [W81XWH-05-1-0265]
  2. Association Neurofibromatoses et Recklinghausen
  3. Canceropole Ile-de France
  4. Institut National du Cancer
  5. ANR
  6. Inserm
  7. Conseil Regional d'Ile-de-France
  8. Ministere de la Recherche

向作者/读者索取更多资源

Merlin is the product of the Nf2 tumor-suppressor gene, and inactivation of Nf2 leads to the development of neural tumors such as schwannomas and meningiomas in humans and mice. Merlin is a member of the ERM (ezrin, radixin and moesin) family of proteins that function as organizers of the actin cytoskeleton. Merlin structure is thought to be similar to that of the ERM proteins, and is held in a closed clamp conformation via intramolecular interactions of its N-terminal FERM (four-point-one, ERM) domain with an alpha-helical C-terminal domain. Like ERMs, merlin can remodel actin-rich cortical structures, yet merlin uniquely inhibits the proliferation of many different cell types. Here, we report that the F2 subdomain of the FERM domain and a domain close to the C-terminus that is defined by residues 532-579 are essential for merlin-mediated inhibition of primary Schwann cell proliferation. Furthermore, we demonstrate that the F1 subdomain of the merlin FERM domain is required for actin colocalization, proper regulation of merlin C-terminal phosphorylation and for remodeling the cytoskeleton, yet is not required for the inhibition of Schwann cell proliferation. Thus, tumor suppression by merlin is independent of its role as an organizer of the actin cytoskeleton in Schwann cells.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma

Irene Paganini, Gabriele Lorenzo Capone, Jeremie Vitte, Roberta Sestini, Anna Laura Putignano, Marco Giovannini, Laura Papi

JOURNAL OF NEURO-ONCOLOGY (2018)

Article Genetics & Heredity

2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis

Michael J. Fisher, Allan J. Belzberg, Peter de Blank, Thomas De Raedt, Florent Elefteriou, Rosalie E. Ferner, Marco Giovannini, Gordon J. Harris, Michel Kalamarides, Matthias A. Karajannis, AeRang Kim, Conxi Lazaro, Lu Q. Le, Wei Li, Robert Listernick, Staci Martin, Helen Morrison, Eric Pasmant, Nancy Ratner, Elisabeth Schorry, Nicole J. Ullrich, David Viskochil, Brian Weiss, Brigitte C. Widemann, Yuan Zhu, Annette Bakker, Eduard Serra

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2018)

Article Oncology

Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development

Marisa A. Fuse, Christine T. Dinh, Jeremie Vitte, Joanna Kirkpatrick, Thomas Mindos, Stephani Klingeman Plati, Juan I. Young, Jie Huang, Annemarie Carlstedt, Maria Clara Franco, Konstantin Brnjos, Jackson Nagamoto, Alejandra M. Petrilli, Alicja J. Copik, Julia N. Soulakova, Olena Bracho, Denise Yan, Rahul Mittal, Rulong Shen, Fred F. Telischi, Helen Morrison, Marco Giovannini, Xue-Zhong Liu, Long-Sheng Chang, Cristina Fernandez-Valle

NEURO-ONCOLOGY (2019)

Article Genetics & Heredity

From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis

Rosalie E. Ferner, Annette Bakker, Ype Elgersma, D. Gareth R. Evans, Marco Giovannini, Eric Legius, Alison Lloyd, Ludwine M. Messiaen, Scott Plotkin, Karlyne M. Reilly, Aaron Schindeler, Miriam J. Smith, Nicole J. Ullrich, Brigitte Widemann, Larry S. Sherman

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2019)

Article Clinical Neurology

Linked-read Sequencing Analysis Reveals Tumor-specific Genome Variation Landscapes in Neurofibromatosis Type 2 (NF2) Patients

Daniel S. Roberts, Rahul Maurya, Yuka Takemon, Jeremie Vitte, Liang Gong, Juanjuan Zhao, Chee-Hong Wong, William Slattery, Kevin A. Peng, Gregory Lekovic, Marc S. Schwartz, Ketan Bulsara, Chew Yee Ngan, Marco Giovannini, Chia-Lin Wei

OTOLOGY & NEUROTOLOGY (2019)

Article Oncology

Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo

Sherif G. Ahmed, Ahmed Abdelnabi, Casey A. Maguire, Mohamed Doha, Jessica E. Sagers, Rebecca M. Lewis, Alona Muzikansky, Marco Giovannini, Anat Stemmer-Rachamimov, Konstantina M. Stankovic, Giulia Fulci, Gary J. Brenner

NEURO-ONCOLOGY (2019)

Article Biochemistry & Molecular Biology

Phosphorylation of Merlin by Aurora A kinase appears necessary for mitotic progression

Vinay Mandati, Laurence Del Maestro, Florent Dingli, Berangere Lombard, Damarys Loew, Nicolas Molinie, Stephane Romero, Daniel Bouvard, Daniel Louvard, Alexis M. Gautreau, Eric Pasmant, Dominique Lallemand

JOURNAL OF BIOLOGICAL CHEMISTRY (2019)

Article Oncology

Cluster of differentiation 44 promotes osteosarcoma progression in mice lacking the tumor suppressor Merlin

Junzhi Ma, Janina Klemm, Monserrat Gerardo-Ramirez, Lucien Frappart, Darko Castven, Diana Becker, Ansgar Zoch, Romain Parent, Birke Bartosch, Kerstin Minnich, Marco Giovannini, Sven Danckwardt, Nils Hartmann, Helen Morrison, Peter Herrlich, Jens U. Marquardt, Monika Hartmann

INTERNATIONAL JOURNAL OF CANCER (2020)

Article Biochemistry & Molecular Biology

The mechano-sensitive response of β1 integrin promotes SRC-positive late endosome recycling and activation of Yes-associated protein

Marc R. Block, Molly Brunner, Theo Ziegelmeyer, Dominique Lallemand, Mylene Pezet, Genevieve Chevalier, Philippe Ronde, Cecile Gauthier-Rouviere, Bernhard Wehrle-Haller, Daniel Bouvard

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Article Genetics & Heredity

Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation

Eric Legius, Ludwine Messiaen, Pierre Wolkenstein, Patrice Pancza, Robert A. Avery, Yemima Berman, Jaishri Blakeley, Dusica Babovic-Vuksanovic, Karin Soares Cunha, Rosalie Ferner, Michael J. Fisher, Jan M. Friedman, David H. Gutmann, Hildegard Kehrer-Sawatzki, Bruce R. Korf, Victor-Felix Mautner, Sirkku Peltonen, Katherine A. Rauen, Vincent Riccardi, Elizabeth Schorry, Anat Stemmer-Rachamimov, David A. Stevenson, Gianluca Tadini, Nicole J. Ullrich, David Viskochil, Katharina Wimmer, Kaleb Yohay, Susan M. Huson, D. Gareth Evans, Scott R. Plotkin

Summary: The study revised the diagnostic criteria for neurofibromatosis type 1 (NF1) and established criteria for Legius syndrome (LGSS) by combining major developments in genetics, ophthalmology, dermatology, and neuroimaging. Consensus on minimal clinical and genetic criteria for diagnosing and differentiating NF1 and LGSS was reached, with recommendations for mosaic forms of these conditions. Continued refinement of these new criteria will be necessary to study their diagnostic properties, reconsider criteria not included, and identify new features of the conditions, hence proposing an initiative to periodically update the diagnostic criteria for NF1 and LGSS.

GENETICS IN MEDICINE (2021)

Article Cell Biology

Deletion of Nf2 in neural crest-derived tongue mesenchyme alters tongue shape and size, Hippo signalling and cell proliferation in a region- and stage-specific manner

Mohamed Ishan, Guiqian Chen, Wenxin Yu, Zhonghou Wang, Marco Giovannini, Xinwei Cao, Hong-Xiang Liu

Summary: The study aimed to understand the roles of tumor suppressor Neurofibromin 2 (Nf2) in neural crest (NC)-derived tongue mesenchyme in regulating Hippo signaling and cell proliferation for proper tongue development. The results showed specific alterations in Hippo signaling activity and cell proliferation in Nf2(cKO) mutants, leading to abnormalities in tongue shape and size at different developmental stages.

CELL PROLIFERATION (2021)

Article Genetics & Heredity

Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation

Scott R. Plotkin, Ludwine Messiaen, Eric Legius, Patrice Pancza, Robert A. Avery, Jaishri O. Blakeley, Dusica Babovic-Vuksanovic, Rosalie Ferner, Michael J. Fisher, Jan M. Friedman, Marco Giovannini, David H. Gutmann, Clemens Oliver Hanemann, Michel Kalamarides, Hildegard Kehrer-Sawatzki, Bruce R. Korf, Victor-Felix Mautner, Mia MacCollin, Laura Papi, Katherine A. Rauen, Vincent Riccardi, Elizabeth Schorry, Miriam J. Smith, Anat Stemmer-Rachamimov, David A. Stevenson, Nicole J. Ullrich, David Viskochil, Katharina Wimmer, Kaleb Yohay, Susan M. Huson, Pierre Wolkenstein, D. Gareth Evans

Summary: The study aims to update the diagnostic criteria for neurofibromatosis type 2 (NF2) and schwannomatosis (SWN) by incorporating recent advances in genetics, ophthalmology, neuropathology, and neuroimaging. The updated criteria include clinical features and genetic testing, emphasizing the phenotypic overlap between the two conditions.

GENETICS IN MEDICINE (2022)

Article Medicine, Research & Experimental

Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2

Shilpa Prabhakar, Roberta L. Beauchamp, Pike See Cheah, Akiko Yoshinaga, Edwina Abou Haidar, Sevda Lule, Gayathri Mani, Katia Maalouf, Anat Stemmer-Rachamimov, David H. Jung, Bradley Welling, Marco Giovannini, Scott R. Plotkin, Casey A. Maguire, Vijaya Ramesh, Xandra O. Breakefield

Summary: Loss of function of the NF2 tumor suppressor gene leads to the formation of certain types of tumors. This study demonstrates that introducing merlin back into NF2-null schwannomas through gene replacement can cause tumor regression. In a mouse model, injection of AAV1-merlin resulted in decreased tumor size, reduced cell division, and increased apoptosis.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)

Article Multidisciplinary Sciences

Cellular mechanisms of heterogeneity in NF2-mutant schwannoma

Christine Chiasson-MacKenzie, Jeremie Vitte, Ching-Hui Liu, Emily A. Wright, Elizabeth A. Flynn, Shannon L. Stott, Marco Giovannini, Andrea I. McClatchey

Summary: Schwannomas are common tumors that develop on cranial and spinal nerves and are associated with neurofibromatosis type 2 (NF2). Despite genetic uniformity, schwannomas exhibit clinical and therapeutic heterogeneity. The mechanism behind this heterogeneity in NF2-mutant schwannomas is unknown.

NATURE COMMUNICATIONS (2023)

Article Biology

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1

Sara H. Isakson, Anthony E. Rizzardi, Alexander W. Coutts, Daniel F. Carlson, Mark N. Kirstein, James Fisher, Jeremie Vitte, Kyle B. Williams, G. Elizabeth Pluhar, Sonika Dahiya, Brigitte C. Widemann, Eva Dombi, Tilat Rizvi, Nancy Ratner, Ludwine Messiaen, Anat O. Stemmer-Rachamimov, Scott C. Fahrenkrug, David H. Gutmann, Marco Giovannini, Christopher L. Moertel, David A. Largaespada, Adrienne L. Watson

COMMUNICATIONS BIOLOGY (2018)

暂无数据